CalciMedica is trading 5.6% higher at $1.12, with no verified company-specific announcement dated October 21, 2026, identified to explain the move. - The CFO resignation news surfaced several days earlier, not today. - Biotech context was positive: XBI is up 2.10%, amid Merck’s announced acquisition of Silence Therapeutics and positive clinical-trial news. - Sector strength may help explain the rise, but no direct connection to CalciMedica has been reported.